Follow
Off-the-shelf CARTs
"Nevertheless, generation of autologous CAR T cell products is extremely time consuming and costly, prompting researchers to explore alternative strategies to overcome these limitations. In this issue of Nature Medicine, Mailankody et al.4 report results of part A of the phase 1 UNIVERSAL clinical trial, which evaluated ALLO-715, an allogeneic off-the-shelf anti-BCMA CAR T cell product."
#CARTcells #Immunology #Immunotherapy #NatureMedicine #MultipleMyeloma #Hematology
